Skip to content

Inspection prep notes · Supply, manufacturing and packaging

Equipment qualification

Also called: IQ/OQ/PQ, requalification

FDA looks less at whether qualification documents exist than at whether the equipment and systems in use today are in a qualified state. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1Manufacturing equipment was not qualified

You have not conducted qualification of critical manufacturing equipment.

FDA Warning Letter · Proquimes S A Productos Quimicos Especializados S.A. · 2021-04-13 · View document

Specifically, You have performed a process validation for the manufacturing of the API [redacted] (DMF# [redacted] using production equipment that have not been qualified.

FDA 483 · MicroBioPharm Japan Co., Ltd · 2026-11-05 · View document

2Equipment was not requalified after it was modified or relocated

Your firm modified your (b)(4) system (number (b)(4) ) in October 2024 by adding a production point of use in the (b)(4) area and replacing the (b)(4) tank with a (b)(4) tank without adequate requalification.

FDA Warning Letter · Island Kinetics, Inc. d.b.a. CoValence Laboratories · 2026-07-21

Additionally, per CC25-042 you moved pellet press [redacted] from room [redacted] to room [redacted] and moved pellet press [redacted] from room [redacted] to room [redacted]. Your firm did not requalify pellet presses after their relocation.

FDA 483 · F.H. Investments Inc dba Asteria Health · 2026-02-10 · View document

3The system producing water or similar utilities for manufacturing and equipment cleaning was not adequately qualified

You failed to adequately qualify your (b)(4) water system that produced water used for equipment cleaning and in formulating your product.

FDA Warning Letter · Colgate-Palmolive/Tom's of Maine, Inc. · 2024-11-19 · View document

Your firm failed to adequately qualify your (b)(4) system to ensure it produces (b)(4) that meets appropriate chemical and microbial attributes for use in your OTC drug products manufacturing and equipment cleaning.

FDA Warning Letter · Integrity Partners Group · 2026-01-20 · View document

4Quality unit review and approval of the requalification was not completed in time

Although the requalification occurred 11/11/2022, to date, the final report has not been approved by the quality unit.

FDA 483 · Wedgewood Connect, LLC · 2024-02-12 · View document

The delay in Quality review process led to utilize the equipment in its failed requalified state

FDA 483 · Merck Teknika LLC · 2026-10-27 · View document

5There was no documentation showing that equipment had been qualified

Additionally, you lacked documentation that the equipment used to manufacture your drug product was qualified and suitable for its intended use.

FDA Warning Letter · Diora Kimya Sanayi ve Ticaret Limited Sirketi · 2024-10-22 · View document

You cannot provide documentation to indicate that equipment used to manufacture, process, package or hold drug product are appropriately designed, qualified and controlled.

FDA 483 · Tropical Seas, Inc. · 2026-10-20 · View document

Questions to check against your procedures

  1. Is any critical manufacturing equipment in use without having been qualified?
  2. Was the production equipment used in process validation qualified beforehand?
  3. Was requalification performed after changes such as adding a point of use, replacing a tank or relocating equipment?
  4. Is the system that produces water for manufacturing and equipment cleaning qualified?
  5. Has the quality unit approved the final requalification report, and is that review completed before the equipment is used?
  6. Can you readily show documentation that equipment is qualified and suitable for its intended use?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-16.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.